403646-47-9

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-2-(trifluoromethoxy)benzoic acid is utilized as a key intermediate in the development of new pharmaceuticals. Its presence in the molecular structure of drugs can influence their pharmacological properties, such as solubility, stability, and bioavailability, thereby enhancing their therapeutic efficacy.
Used in Agrochemical Development:
In the agrochemical industry, 5-Bromo-2-(trifluoromethoxy)benzoic acid serves as a crucial component in the creation of novel pesticides and herbicides. Its unique structure can contribute to the effectiveness of these chemicals in controlling pests and weeds, thus supporting agricultural productivity.
Used in Organic Synthesis:
5-Bromo-2-(trifluoromethoxy)benzoic acid is employed as a versatile reagent in organic synthesis. Its halogen and trifluoromethoxy substituents provide interesting chemical properties that can be exploited in various synthetic pathways, leading to the formation of a wide range of organic compounds.
Used as a Research Tool in Laboratory Settings:
Due to its unique structure and properties, 5-Bromo-2-(trifluoromethoxy)benzoic acid is also used as a research tool in academic and industrial laboratories. It can be employed in studies aimed at understanding the effects of specific functional groups on chemical reactivity and in the development of new synthetic methodologies.

InChI:InChI=1/C8H4BrF3O3/c9-4-1-2-6(15-8(10,11)12)5(3-4)7(13)14/h1-3H,(H,13,14)

Upstream product

• 124-38-9 carbon dioxide 
• 773135-66-3 ethyl 5-bromo-2-(trifluoromethoxy)benzoate 
• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 

Downstream Products

• 1262620-41-6 C₁₀H₈BrF₃N₂O₃ 
• 1262620-37-0 2-(5-bromo-2-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Alpha-alkyl substituted N-acyltryptophanols

The present invention relates to α-alkyl substituted N-acyltryptophanols of the formula I in which R1, R2, R3, R4, R5, R6, Q, X and W have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

Cyanomethyl substituted N-Acyl Tryptamines

The present invention relates to cyanomethyl substituted N-acyl tryptamines of the formula I in which R1, R2, R3, R4, R5, Q, X and W have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and

Melanocortin-4 receptor binding compounds and methods of use thereof

Provided are MC4-R binding compounds of the formula XVII: wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are a

1,2-Didehydro-3- and -4-(trifluoromethoxy)benzene: The "aryne" route to 1- and 2-(trifluoromethoxy)naphthalenes

Upon treatment of 1-bromo-2-(trifluoromethoxy)benzene with lithium diisopropylamide (LIDA) at -100°C, 3-bromo-2-(trifluoromethoxy)phenyllithium is generated. It can be trapped as such, but isomerizes to afford 2-bromo-6-(trifluoromethoxy)phenyllithium whe